Ga-68 PSMA PET对PIRADS 4-5前列腺癌的诊断价值
Ga-68 PSMA PET对主要肿瘤检出率100%,对非主要肿瘤检出率53.3%;PIRADS 4组中PET定位升级肿瘤更优,但mpMRI预测包膜外侵犯和精囊侵犯优于PET。
要点
- Ga-68 PSMA PET检出全部主要肿瘤,包括13例mpMRI漏诊者。
- PIRADS 4组中PET定位升级肿瘤优于mpMRI。
- mpMRI预测包膜外侵犯和精囊侵犯优于PET,联合可提高检出率。
核心结论
- Ga-68 PSMA PET对PIRADS 4索引病灶患者的主要肿瘤、非主要肿瘤、升级和不良病理诊断准确性优于mpMRI。
- 但mpMRI预测包膜外侵犯和精囊侵犯优于Ga-68 PSMA PET。
研究设计与样本
- 比较根治标本中主要肿瘤和非主要肿瘤的定位、分级和体积特征与mpMRI及PET索引病灶的对应关系。
主要发现
- Ga-68 PSMA PET对主要肿瘤检出率为100%,包括13例mpMRI未检出者。
- 45例根治标本报告非主要肿瘤,Ga-68 PSMA PET准确检出24例(53.3%)。
- PIRADS 4组6例(12.2%)和PIRADS 5组8例(25%)出现升级;PIRADS 4组中PET定位全部升级肿瘤,mpMRI漏诊2/6(33.3%)。
- mpMRI对包膜外侵犯和精囊侵犯总检出率分别为51.1%和53.8%,PET分别为27.9%和30.7%;联合后分别提高至65.1%和61.5%。
- 10例淋巴结阳性患者中,Ga-68 PSMA PET检出6例,mpMRI未检出任何一例。
临床怎么用
- 对于PIRADS 4-5索引病灶的前列腺癌患者,Ga-68 PSMA PET可作为mpMRI的补充用于检测主要肿瘤、非主要肿瘤和升级。
- 评估包膜外侵犯和精囊侵犯时,mpMRI仍应作为首选,联合PET可提高检出率。
- Ga-68 PSMA PET对淋巴结阳性检出优于mpMRI,可考虑用于分期评估。
局限性
- 回顾性研究设计。
- 未报告诊断准确性指标如敏感度、特异度等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the additive role of Ga-68 PSMA PET as a primary staging tool in patients bearing prostate cancer in single PIRADS 4 or 5 index lesions. METHODS: Eighty-one biopsy-naive patients with preoperative mpMRI and Ga-68 PSMA PET who underwent radical prostatectomy (RP) were evaluated retrospectively. Forty-nine patients had PIRADS 4 and 32 had PIRADS 5 index lesions. The localization, grade, and volumetric properties of dominant (DT) and non-dominant tumors (NDT) in RP were compared to the index lesions of mpMRI and Ga-68 PSMA PET. RESULTS: The median age and PSA level were 62 (IQR; 59-69) years and 7 (IQR; 2-8) ng/ml, respectively. Ga-68 PSMA PET detected DTs in 100% of the patients including 13 patients in whom mpMR failed. In 45 patients an NDT was reported in RP. Ga-68 PSMA PET accurately detected NDT in 24 of 45 (53.3%) patients. Six patients (12.2%) in PIRADS 4 and 8 (25%) in PIRADS 5 group showed upgrading. In PIRADS 4, Ga-68 PSMA PET localized DT in all patients with upgraded tumors whereas mpMRI missed exact location in 2 of 6 (33.3%). In PIRADS 5 both mpMRI and Ga-68 PSMA PET accurately located all DTs. Overall detection rates of extracapsular extension (ECE) and seminal vesicle invasion (SVI) by mpMRI were 51.1% and 53.8%, respectively. Ga-68 PSMA PET detected ECE and SVI in 27.9% and 30.7%, respectively. When mpMRI and Ga-68 PSMA PET were used in combination detection rates of ECE and SVI increased to 65.1 and 61.5%. Ga-68 PSMA PET-detected six of ten patients with positive lymph nodes whereas mpMRI could not identify any. CONCLUSIONS: Ga-68 PSMA PET has a better diagnostic accuracy in detecting DT, NDT, upgrading, adverse pathology in patients with PIRADS 4 index lesions. However, mpMRI better predicted ECE and SVI than Ga-68 PSMA PET.
引用
- Koseoglu E, Kordan Y, Kilic M, et al. Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4-5 index lesions undergoing radical prostatectomy. Prostate Cancer Prostatic Dis. 2020. PMID: 32826958. doi:10.1038/s41391-020-00270-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。